Emphasizing this notion, locus perturbations leading to dominant negative PARP-1 proteins or decreased PARP-1 expression have been detected in Diffuse large B cell lymphoma (54), a disease characterized by aberrant somatic hypermutation (55), but nonetheless PARP inhibitor combination therapy is employed in the treatment of human B cell malignancies (56,57). This evidence concerns the gene PARP1 and diffuse large B-cell lymphoma.